Evidence map›Paper›PMID 24400117›Full record

ArticlePloS one2014

Matrix stiffness affects endocytic uptake of MK2-inhibitor peptides.

Jamie L Brugnano, Alyssa Panitch

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Matrix stiffness regulates microvesicle-induced fibroblast activation.American journal of physiology. Cell physiology · 2019
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jamie L BrugnanoWeldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, United States of America.
Alyssa PanitchWeldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, United States of America.
Purdue University West Lafayette · US

Funding

Improved Therapeutics for Drug Eluting StentsR01HL106792 · NHLBI · PURDUE UNIVERSITY · PI PANITCH, ALYSSA · 2011 to 2014
$1.5M
NHLBI NIH HHS R01 HL106792NHLBI NIH HHS R01HL106792
6 · The paper itself

Abstract

In this study, the role of substrate stiffness on the endocytic uptake of a cell-penetrating peptide was investigated. The cell-penetrating peptide, an inhibitor of mitogen-activated protein kinase activated protein kinase II (MK2), enters a primary mesothelial cell line predominantly through caveolae. Using tissue culture polystyrene and polyacrylamide gels of varying stiffness for cell culture, and flow cytometry quantification and enzyme-linked immunoassays (ELISA) for uptake assays, we showed that the amount of uptake of the peptide is increased on soft substrates. Further, peptide uptake per cell increased at lower cell density. The improved uptake seen on soft substrates in vitro better correlates with in vivo functional studies where 10-100 µM concentrations of the MK2 inhibitor cell penetrating peptide demonstrated functional activity in several disease models. Additional characterization showed actin polymerization did not affect uptake, while microtubule polymerization had a profound effect on uptake. This work demonstrates that cell culture substrate stiffness can play a role in endocytic uptake, and may be an important consideration to improve correlations between in vitro and in vivo drug efficacy.

Indexed as

Amino Acid SequenceCell LineCell-Penetrating PeptidesCytokinesEndocytosisHumansIntracellular Signaling Peptides and ProteinsMAP-Kinase-Activated Kinase 2MicrotubulesProtein Kinase InhibitorsProtein MultimerizationProtein Serine-Threonine KinasesCell-Penetrating PeptidesCytokinesIntracellular Signaling Peptides and ProteinsMAP-Kinase-Activated Kinase 2Protein Kinase InhibitorsProtein Serine-Threonine Kinases

Identifiers

PMID24400117
PMCPMC3882240
OpenAlexW2058873673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.